Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 2/20 | 0.50 | |
| ▸ | NQO1 | P15559 | 4/20 | 0.41 |
| ▸ | POR | P16435 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8336398 | 0.87 | PDF (0.41) | PDFNQO1PORCES1CES2 | |
| SCHEMBL17104861 | 0.71 | NQO1 (0.32) | NQO1POR | |
| SCHEMBL14236260 | 0.68 | NQO1 (0.33) | NQO1POR | |
| SCHEMBL290186 | 0.68 | PDF (1.00) | PDFMAPTTDP1KDM5A | |
| SCHEMBL783241 | 0.66 | PDF (1.00) | PDFMAPTTDP1KDM5A | |
| SCHEMBL10459823 | 0.61 | NQO1 (0.59) | NQO1PORCES1CES2KDM1A | |
| SCHEMBL8310508 | 0.60 | ACHE (0.41) | PDFMAPTTDP1 | |
| SCHEMBL5940262 | 0.59 | NQO1 (0.68) | NQO1PORCES1CES2KDM1A | |
| SCHEMBL14253089 | 0.58 | CDC25B (0.48) | NQO1PORPOLBMAPTBLM | |
| SCHEMBL30029972 | 0.58 | CDC25B (0.48) | NQO1PORPOLBMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532390-B1 | Pharmaceutical composition for liver diseases. | MD BIOALPHA CO LTD (KR) | 2016-08-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| EP-1848432-B1 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO LTD (KR) | 2013-07-17 | — | — | EP | disclosed |
| US-8466141-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2013-06-18 | — | — | US | disclosed |
| EP-2532388-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532389-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532390-A2 | Pharmaceutical composition for obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| US-20120114714-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION | KWAK TAEHWAN (KR) | 2012-05-10 | — | — | US | disclosed |
| US-20110020448-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE, INC. (KR) | 2011-01-27 | — | — | US | disclosed |
| US-20100255054-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | KT & G CO., LTD. (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | KT & G CO., LTD. (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114714-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION | PDE3A, PDE3B, PDE2A | PDF 664/4885NQO1 377/4885POR 413/4885 |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | SLC25A20, SLC25A1, PC | PDF 33/4885NQO1 237/4885POR 632/4885 |
| US-20110020448-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | PDE3A, SLC5A1, GUCY1B1 | PDF 2277/4885NQO1 582/4885POR 511/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | PDF 21/4885NQO1 260/4885POR 902/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | PDF 21/4885NQO1 250/4885POR 909/4885 |
| US-20100255054-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | TGFB1, TGFB2, PCSK9 | PDF 4277/4885NQO1 2070/4885POR 1633/4885 |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | PDE3A, PDE3B, PDE2A | PDF 425/4885NQO1 406/4885POR 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.